Ready 8-Ks
3
Latest filing
November 12, 2026, 4:20 PM ET
Top materiality
0.75
Event mix
earnings ×2 · other_material ×1
Sentiment
2 pos · 0 neg · 1 neu
Recent 8-K filings for SCTX
Highest-materiality recent filing
Scribe Therapeutics Q2 2026 net loss $6.5M; cash $43M plus $140.6M IPO proceeds fund to H1 2029
- Q2 net loss $6.5M ($2.62/share) vs $9.9M ($4.08) YoY; collaboration revenue $1.9M vs $4.9M.
- Cash & marketable securities $43.0M at 6/30/26; July IPO + Sanofi placement raised $155.5M gross, $140.6M net.
-
Scribe Therapeutics Q3 2026 net loss $9.9M ($0.68/sh); $174.2M cash funds operations into 1H 2029
Net loss $9.9M ($0.68 per basic and diluted share) vs $6.5M net loss in Q2 2026; R&D $8.3M, G&A $4.2M, collaboration revenue $1.6M.
-
Scribe Therapeutics Q2 2026 net loss $6.5M; cash $43M plus $140.6M IPO proceeds fund to H1 2029
Q2 net loss $6.5M ($2.62/share) vs $9.9M ($4.08) YoY; collaboration revenue $1.9M vs $4.9M.
-
Scribe Therapeutics adopts amended charter and bylaws upon closing of IPO
Filed Amended and Restated Certificate of Incorporation and Bylaws effective July 27, 2026.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.50 · Most common event earnings